Soligenix Files Proxy Statement for Annual Meeting
Ticker: SNGX · Form: DEFA14A · Filed: May 29, 2024 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | DEFA14A |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
TL;DR
SOLIGENIX proxy filing is out - shareholders vote soon!
AI Summary
Soligenix, Inc. filed a Definitive Additional Materials proxy statement on May 29, 2024. This filing relates to the company's solicitation of proxies for its upcoming annual meeting. The document provides details regarding the matters to be voted on by shareholders, including the election of directors and other corporate governance issues.
Why It Matters
This filing is important for shareholders as it outlines the agenda for the annual meeting and provides information necessary to cast their votes on key company decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating immediate financial distress or significant new risks.
Key Players & Entities
- SOLIGENIX, INC. (company) — Registrant
- 0000812796 (company) — Central Index Key
- 20240529 (date) — Filing Date
- DEFA14A (document_type) — Filing Type
FAQ
What type of filing is this DEFA14A for Soligenix, Inc.?
This is a Definitive Additional Materials filing, indicating it's supplemental information for proxy solicitation.
When was this filing made?
The filing was made on May 29, 2024.
What is the primary purpose of a DEFA14A filing?
A DEFA14A filing is used by a company to solicit proxies from its shareholders for an upcoming meeting.
What is Soligenix, Inc.'s SIC code?
Soligenix, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Has Soligenix, Inc. undergone previous name changes?
Yes, the company was formerly known as DOR BIOPHARMA INC (name change on 20020329) and ENDOREX CORP (name change on 19960916), and IMMUNOTHERAPEUTICS INC (name change on 19920703).
Filing Stats: 166 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-05-29 16:05:07
Filing Documents
- tmb-20240529xdefa14a.htm (DEFA14A) — 10KB
- 0001558370-24-008727.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement. Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement. Definitive Additional Materials. Soliciting Material Pursuant to 240.14a-12 SOLIGENIX, INC. (Name of Registrant as Specified in Its Charter) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. [The following is a post made to the Company's social media pages on Twitter, Facebook, Instagram and LinkedIn on May 29, 2024] LAST DAY TO VOTE! Participate in our Annual Meeting of Shareholders. Go to www.proxyvote.com or call 1-800-690-6903 (have your proxy card available) to vote. If you do NOT have your proxy card available, call our proxy solicitor, Alliance Advisors at 1-833-782-7145.